NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE FINAL APPRAISAL DETERMINATION FOR LUCENTIS

That this House welcomes the Final Appraisal Determination issued by the National Institute for Health and Clinical Excellence in April which establishes that treatment with Lucentis is cost-effective for the vast majority of patients with wet age-related macular degeneration; notes that more than one third of primary care trusts have already implemented the recommendations; further notes that the Royal College of Ophthalmologists is recommending full implementation of Final Guidance within the normal three month period; and urges the Secretary of State to follow this expert advice.